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http://dx.doi.org/10.1016/j.jmii.2013Background: Extended-spectrum b-lactamase (ESBL)-producing pathogens have been increas-
ingly identified in community-onset urinary tract infection (UTI). This study was conducted
to determine the epidemiology and risk factors of community-onset UTI caused by ESBL-
producing pathogens, and to determine the correlation of antimicrobial resistance with ESBL
detected by phenotypic and genotypic methods.
Methods: The study was conducted from December 2010 to January 2012. Patients with
community-onset UTI caused by Enterobacteriaceae were enrolled from the emergency depart-
ment. The production of ESBLwas determined by the phenotypicmethod (using the combineddisk
test) or by the genotypic method (using polymerase chain reaction detection). The patients’ med-
ical records were reviewed and risk factors were analyzed by multivariate analysis.Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2,
m.tw (Y.-T. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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ESBL-producing uropathogens 169Results: A total of 376 patients were enrolled and 393 isolates from urine culture were analyzed.
Escherichia coli was the most commonly isolated species (259/393 isolates; 65.9%), followed by
Klebsiella pneumoniae (42/393 isolates; 10.7%). Fifty-three (13.5%) isolates were phenotypically
positive for ESBL production. Nine (2.3%) isolates were phenotypically positive for both ESBL and
AmpC b-lactamase (AmpC) production. Nasogastric tube placement [odds ratio (OR) 2.230; 95%
confidence interval (CI) 1.244e3.997; pZ 0.007] and hospitalization within the previous 3months
(OR 2.567, 95% CI 1.448e4.551, pZ 0.001) were independently associated with the acquisition of
ESBL-producing pathogens in community-onset UTI. The ESBL phenotype had a better correlation
with resistance to third-generation cephalosporins, compared to the ESBL-positive genotype.
Conclusion: In our study, nasogastric tube placement and hospitalization within the previous 3
months were significantly associated with the acquisition of ESBL-producing pathogens in
community-onset UTI.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Multidrug-resistant bacteria are an emerging challenge for
clinicians with respect to antimicrobial treatment and
infection control in hospitals. Extended-spectrum b-lacta-
mase (ESBL)-producing Gram-negative bacteria are one of
the most annoying groups of pathogens that have become a
major problem in hospitalized patients since the early
1990s.1 However, these pathogens have further spread to
nursing homes and the community in recent years.2e4
Since 1998, community-onset urinary tract infection
(UTI) caused by ESBL-producing Enterobacteriaceae has
been increasingly reported.3,4 Patients with community-
acquired UTI caused by ESBL-producing Escherichia coli
and Klebsiella pneumoniae had longer hospital stays and
higher costs for antimicrobial use.5 However, the case
numbers used in previous studies were rather small.5e8
Accurately identifying ESBLs by using conventional pheno-
typic methods is sometimes difficult in practice. Identifi-
cation is also made more difficult because ESBL-producing
Enterobacteriaceae increasingly overproduce AmpC b-lac-
tamases (AmpC) concomitantly.9e12 All equivocations indi-
cate a need for further investigation. The aim of this large-
scale prospective cohort study is to determine the epide-
miology and risk factors of ESBL-producing Enter-
obacteriaceae, which were tested by phenotypic methods
and by genotypic methods in community-onset UTI in a
medical center in northern Taiwan.Methods
Hospital setting and patients
The Taipei Veterans General Hospital is a 2900-bed tertiary
care teaching hospital in northern Taiwan. Adult patients
who were admitted to the Taipei Veterans General Hospital
with a diagnosis of community-onset UTI caused by Enter-
obacteriaceae were eligible for inclusion in this study if
they required initial parental antimicrobial therapy. Pa-
tients were initially enrolled in the study, based on a pos-
itive urinalysis result at the Emergency Department. They
were then evaluated only if they met the criteria for apositive urine culture [i.e., at least 1  105 colony-forming
units per milliliter (CFU/mL) of Enterobacteriaceae]. A
single isolate was included from a patient, unless the cul-
ture grew more than one species. The exclusion criteria
were pregnancy or lactation in women, complete obstruc-
tion of the urinary tract, and perinephric or intrarenal ab-
scess. Male patients with a history or physical findings
suggestive of acute or chronic prostatitis were also
excluded. This study was approved by the Institutional
Review Board of the Taipei Veterans General Hospital
(VGHIRB; No. 201003025IC).
Definitions
Community-onset infection was defined as an infection
diagnosed within 48 hours after admission. Community
onset infections included infections that were classified as
community-acquired or as healthcare-associated, if either
of the following criteria were present13: (1) the patient
received intravenous therapy, wound care, or specialized
nursing care at home or in an outpatient clinic, or received
renal dialysis in the previous 30 days; and (2) the patient
had more than 48 hours of hospital admission or had resided
in a nursing home or longterm care facility within the
previous 90 days. The criteria for UTIs were clinical signs
and/or symptoms of UTIs (e.g., fever > 38C, urgency,
frequency, dysuria, or suprapubic tenderness) with no other
recognized cause; pyuria (i.e., urine specimen with 10
white blood cells/mm3) and a positive urine culture
(1  105 CFU/mL of a uropathogen).
Bacteriology and antimicrobial susceptibility
testing
Enterobacteriaceae were identified by using the VITEK 2
system (bioMe´rieux, Marcy l’Etoile, France). In vitro sus-
ceptibility testing to commonly used antibiotics was per-
formed by using agar dilution methods. The results were
interpreted in accordance with the Clinical Laboratory
Standards Institute (CLSI).9 We used CLSI ESBL confirmatory
test with disks containing cefotaxime (CTX; 30 mg) and
ceftazidime (CAZ; 30 mg) with and without clavulanic acid
(CLA; 10 mg) on MuellereHinton agar.9 An increase in the
Table 1 ESBL phenotypes of Enterobacteriaceae causing
community-onset urinary tract infections
Bacteria species Phenotype
N ESBL only,
N (%)
ESBL þ
AmpC, N (%)
Citrobacter amalonaticus 1 0 0
Citrobacter diversus 6 0 0
Citrobacter freundii 4 0 0
Enterobacter aerogenes 3 0 1 (33.3)
Enterobacter cloacae 6 0 0
Enterobacter gergoviae 1 0 0
Escherichia coli 259 36 (13.9) 2 (0.8)
Klebsiella oxytoca 1 0 0
Klebsiella pneumoniae 42 11 (26.2) 6 (14.3)
Morganella morganii 9 1 (11.1) 0
Proteus mirabilis 36 3 (8.3) 0
Proteus penneri 1 0 0
Proteus vulgaris 1 0 0
Providencia alcalifaciens 1 0 0
Providencia rettgeri 5 2 (40.0) 0
Providencia stuartii 3 0 0
Serratia marcescens 13 0 0
Serratia species 1 0 0
Total 393 53 (13.5) 9 (2.3)
AmpC Z AmpC b-lactamase; ESBL Z extended-spectrum b-
lactamase.
170 C.-H. Kung et al.zone diameter of 5 mm in the presence of CLA was
considered phenotypic confirmation of ESBL production. E.
coli ATCC 25922 and K. pneumoniae ATCC 700603 were used
as the negative and positive controls, respectively, and
were the routine quality control. Because ESBL can be
masked by the expression of AmpC, a modified disk
potentiation test using 3-aminophenylboronic acid (APB;
400 mg) was conducted to enhance the detection of ESBLs in
isolates that may simultaneously harbor plasmid-borne
AmpCs or chromosomal AmpC gene.14e16 A positive result
for ESBLs was a 5 mm increase in the zone diameter of
CTX/CLA and/or CAZ/CLA disks that were tested in com-
bination with APB (i.e., CTX/CLA/APB and/or CAZ/CLA/Table 2 Genotype analysis of phenotypical ESBL-positive E
infections
Bacterial species
Total no. of isolates PER SH
Enterobacter aerogenes 1 0 0
Escherichia coli 38 0 6
Klebsiella pneumoniae 17 0 16
Morganella morganii 1 0 0
Proteus mirabilis 3 0 0
Providencia rettgeri 2 0 0
Total 62 0 22
ESBL Z extended-spectrum b-lactamase.APB) versus CTX and/or CAZ disks containing APB (i.e.,
CTX/APB and/or CAZ/APB). Polymerase chain reaction
(PCR) testing of ESBL-positive isolates for known ESBL genes
was performed by using specific primers for blaTEM, blaSHV,
blaCTx-M, blaToho, blaVEB, and blaPER.
17,18
Statistical analysis
Descriptive statistics were calculated for baseline de-
mographic and clinical variables and the prevalence of ESBL
(including those with and without AmpC) among Enter-
obacteriaceae that cause community-onset UTIs. Univari-
ate analysis was performed by using two-sided Student t
tests, Chi square tests, and Fisher’s exact tests, as appro-
priate. Univariate analysis, followed by multivariable lo-
gistic regression analysis, was performed to identify the risk
factors of community-onset UTIs caused by ESBL-positive
Enterobacteriaceae. We also used univariate analysis, fol-
lowed by multivariable logistic regression analysis, to
identify the genes that were relevant to the ESBL-positive
phenotype. The variables included in multivariate analysis
were identified in the univariate analysis (p < 0.10) and
were implicated in previous studies or were biologically
plausible. Prior to analysis, the variables were assessed for
collinearity. All analyses were performed with the SPSS
version 19.0 software (SPSS, Chicago, IL, USA). All statisti-
cal tests were two-tailed. A p value < 0.05 was considered
statistically significant.
Results
A total of 376 patients with community-onset UTI caused by
Enterobacteriaceae were enrolled and 393 isolates from
the patients’ urine cultures were collected and analyzed.
E. coli was the most commonly isolated species (259/393
isolates; 65.9%), followed by K. pneumoniae (42/393 iso-
lates; 10.7%), Proteus mirabilis (35/393 isolates; 8.9%), and
Serratia marcescens (13/393 isolates; 3.3%). Fifty three
(13.5%) isolates were phenotypically positive for ESBL pro-
duction. E. coli (36 isolates, 67.9%) was the most common
pathogen and K. pneumoniae (11 isolates; 20.8%) was the
second-most common pathogen (Table 1). Nine (2.3%) iso-
latesdsix K. pneumoniae, two E. coli, and one Enter-
obacter aerogenesdwere phenotypically positive for ESBLnterobacteriaceae causing community-onset urinary tract
No. of isolates carrying
V TEM VEB CTX-M/Toho No gene detected
0 0 0 1
8 2 31 4
3 0 12 1
1 1 1 0
0 0 3 0
0 0 1 1
13 3 48 6
Table 3 Risk factors for the acquisition of phenotypically ESBL-positive Enterobacteriaceae
Characteristic Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Nasogastric tube use 2.763 (1.575e4.847) <0.001 2.230 (1.244e3.997) 0.007
Chronic kidney disease 2.053 (1.104e3.816) 0.023
Cerebral vascular accident 1.809 (1.031e3.175) 0.039
Bedridden 1.848 (1.057e3.231) 0.031
Foley catheter 2.075 (1.198e3.596) 0.009
Diagnosis of UTI within 1 year 2.205 (1.265e3.844) 0.005
Antibiotics exposure within 3 monthsa
Penicillins with/without a b-lactamase inhibitor 2.412 (1.287e4.519) 0.006
Cephalosporins 2.158 (1.230e3.787) 0.007
Fluoroquinolones 3.038 (1.554e5.940) 0.001
Hospitalization within the previous 3 months 3.034 (1.743e5.284) <0.001 2.567 (1.448e4.551) 0.001
a Aminoglycosides, carbapenems, tetracyclines (including tigeclcyine), trimethoprim/sulfamethoxazole, colimycin, sulbactam, mon-
obactam are excluded because of the small case number.
CI Z confidence interval; ESBL Z extended-spectrum b-lactamase; OR Z odds ratio; UTI Z urinary tract infection.
ESBL-producing uropathogens 171production and AmpC b-lactamase production. There were
138 ESBL genes detected in 62 phenotypical ESBL-positive
isolates. Of the 62 phenotypical ESBL-positive isolates, six
isolates did not have the ESBL gene. The genes blaCTx-M plus
blaToho were the most commonly detected genes (100/138
isolates; 72.5%), followed by blaSHV (22/138 genes; 15.9%;
Table 2).
Table 3 shows the risk factors for phenotypically ESBL-
positive Enterobacteriaceae in community onset UTI.
Multivariate analysis showed that nasogastric tube place-
ment [odds ratio (OR) 2.230; 95% confidence interval (CI)Table 4 Correlation of ESBL phenotype and genotype with anti
Phenotype
ESBL(e)
Phenotype
ESBL(þ)
Cefazolin 99/330 (30.0) 57/62 (91.9)
Cefuroxime 60/315 (19.0) 57/61 (93.4)
Cefmetazole 46/316 (14.6) 17/61 (27.9)
Cefoxitin 0/14 0/1
Flomoxef 30/316 (9.5) 13/61 (21.3)
Cefotaxime/ceftriaxone 39/330 (11.8) 52/62 (83.9)
Ceftazidime 31/329 (9.4) 48/62 (77.4)
Cefepime/cefpirome 6/329 (1.8) 46/61 (75.4)
Ampicillin 252/330 (76.4) 60/62 (96.8)
Ampicillin/sulbactam 89/329 (27.1) 32/61 (52.5)
Piperacillin/tazobactam 5/315 (1.6) 10/60 (16.7)
Gentamicin 60/330 (18.2) 24/62 (38.7)
Amikacin 0/14 0/1
Ciprofloxacin 62/327 (19.0) 42/61 (68.9)
Levofloxacin 60/329 (18.2) 41/61 (67.2)
Ertapenem 1/330 (0.3) 0/62 (0.0)
Imipenem 1/328 (0.3) 1/60 (1.7)
Tigecycline 0/13 0/1
Trimethoprim/
sulfamethoxazole
133/316 (42.1) 42/60 (70.0)
ESBL Z extended-spectrum b-lactamase.1.244e3.997; p Z 0.007] and hospitalization within the
previous 3 months (OR 2.567; 95% CI 1.448e4.551;
p Z 0.001) were independently associated with ESBL-
producing pathogens in community-onset UTI. The ESBL-
positive phenotype showed a better correlation with
resistance to third-generation cephalosporins, compared to
bacteria with the ESBL-positive genotype (Table 4). In
addition, phenotypically positive ESBL Enterobacteriaceae
exhibited resistance not only to cephalosporins but to
noncephalosporin antibiotics such as the fluoroquinolones
and trimethoprim/sulfamethoxazole.microbial susceptibilities–>
Resistance rate, n/N (%)
p Genotype
ESBL(e)
Genotype
ESBL(þ)
p
<0.001 77/202 (38.1) 79/191 (41.4) 0.580
<0.001 50/192 (26.0) 67/184 (36.4) 0.039
0.018 34/193 (17.6) 29/184 (15.8) 0.730
0/9 0/7
0.015 22/193 (11.4) 21/184 (11.4) > 0.99
<0.001 31/202 (15.3) 60/191 (31.4) <0.001
<0.001 23/202 (11.4) 56/190 (29.5) <0.001
<0.001 7/202 (3.5) 45/189 (23.8) <0.001
<0.001 145/202 (71.8) 167/191 (87.4) <0.001
<0.001 63/202 (31.2) 58/189 (30.7) > 0.99
<0.001 2/193 (1.0) 13/183 (7.1) 0.006
0.001 38/202 (18.8) 46/191 (24.1) 0.250
0/9 0/7
<0.001 42/201 (20.9) 62/188 (33.0) 0.010
<0.001 40/202 (19.8) 61/189 (32.3) 0.007
> 0.99 1/202 (0.5) 0/191 (0.0) > 0.99
0.286 1/200 (0.5) 1/188 (0.5) > 0.99
0/9 0/6
<0.001 76/193 (39.4) 99/183 (54.1) 0.006
Table 5 Univariate and multivariate analyses of gene type correlation with positive phenotype in the genotypical positive
isolates
ESBL gene Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
blaSHV 0.785 (0.416e1.480) 0.454
blaTEM 0.316 (0.156e0.640) 0.001
blaVEB 7.585 (0.772e74.557) 0.082 16.476 (1.194e227.294) 0.036
blaCTx-M/Toho 13.286 (5.779e30.543) <0.001 14.699 (6.143e35.172) <0.001
CI Z confidence interval; ESBL Z extended-spectrum b-lactamase; OR Z odds ratio.
172 C.-H. Kung et al.There were 56 phenotypical positive isolates in 191
genotypical positive isolates. In the 191 genotypically ESBL-
positive isolates, the presence of blaVEB (OR 16.476;
p Z 0.036) or blaCTx-M/Toho (OR 14.699; p < 0.001) were
independent risk factors for the ESBL-positive phenotype
(Table 5).Discussion
This prospective study, which was conducted in a tertiary
medical center, found that approximately 15% of E. coli and
40% of K. pneumoniae produced ESBL b-lactamases. This
indicates that ESBL-producing Enterobacteriaceae are no
longer a nosocomial problem, but are a growing compre-
hensive issue in community-onset UTIs. Among the ESBL-
producing isolates, pathogens carrying the blaCTx-M genes
were the most prevalent in the community. The ESBL
phenotype, rather than the ESBL genotype, had a better
predictive value for in vitro susceptibility to the third-
generation cephalosporins. The use of nasogastric tubes
and hospitalization within the previous 3 months were the
most important risk factors for the acquisition of ESBL-
positive pathogens in people with community-onset UTIs.
Our study showed a higher prevalence of ESBL-positive
E. coli and K. pneumoniae, compared to a previous study
conducted in 2010 at another medical center in northern
Taiwan.5 One Korean study showed an even higher preva-
lence rate in ESBL-positive E. coli.19 In this study, the ESBL-
positive rate of Enterobacteriaceae causing community-
onset UTIs was higher than the ESBL-positive rate of path-
ogens causing nosocomial infections in Spain (12% in 2003),
Italy (7.4% in 2006), and Denmark (2.8% in 2012).20e22 The
results indicated that ESBL-producing Enterobacteriaceae
have emerged as important pathogens in community set-
tings in Taiwan and in other countries.
In our study, CTX-M was the most popular b-lactamase
carried by the Enterobacteriaceae that cause community-
onset UTIs; this was consistent with the results of past
studies conducted in four continents.23e32
The gene blaToho was considered with blaCTx-M because
of their similar structure.1 In a previous review in Taiwan,
blaSHV and blaCTx-M were the most common genes identified
from Enterobacteriaceae isolated from various clinical
samples of nosocomial and community-acquired in-
fections.33 Our study was confined to community-onset
urinary tract infections, which provides a valuable molec-
ular epidemiological data of emerging ESBL-producing
Enterobacteriaceae in northern Taiwan hospitals. Isolatescarrying blaVEB or blaCTx-M/Toho had a higher frequency of
the ESBL-positive phenotype. Further investigation may be
needed to determine its mechanism and clinical
significance.
Phenotypical ESBL-positive bacteria exhibited resistance
not only to cephalosporins but also to noncephalosporins
such as the fluoroquinolones and trimethoprim/sulfameth-
oxazole because ESBL encoding plasmids may carry genes
that encode resistance to other classes of antibiotics such
as the fluoroquinolones and sulfonamides.34,35 Thus,
limited antibiotic choices are available for treating in-
fections caused by these multidrug-resistant strains. In this
circumstance, the antibiotics piperacillin/tazobactam,
ertapenem, or imipenem are indicated for treatment.7,36
Nasogastric tube usage and hospitalization within the
previous 3 months were independent risk factors for ESBL-
producing isolates in our study. One study from southern
Taiwan showed hospitalization within the previous 6
months and antibiotic use within the previous 60 days are
risk factors for ESBL-producing Enterobacteriaceae causing
community-onset UTIs.37 Nasogastric tube usage and hos-
pitalization in the previous 3 months are two of many risk
factors that have been mentioned previously.1 Previous
studies found that nasogastric tube usage was a risk factor
for infections caused by multidrug-resistant microbes such
as ESBL pathogens and methicillin-resistant Staphylococcus
aureus.1,38e40 Patients with nasogastric tubes are prone to
have more manipulations (e.g., regular replacement of a
new tube) performed by nursing home or emergency
department staff. These manipulations and frequent hos-
pital visits may provide ESBL pathogens an opportunity for
further colonization. Further studies are needed to estab-
lish possible mechanisms of ESBL pathogen colonization via
indwelling catheters such as a nasogastric tube.
This prospective study provided the risk factors for
community-onset urinary tract infection caused by
extended-spectrum b-lactamase-producing Enter-
obacteriaceae, but it still had some limitations.
First, the clinical samples were screened by a double-
disk synergy test and then confirmed by PCR assay. How-
ever, no known ESBL genes were detected in six of the 62
phenotypical ESBL-positive isolates. A more specific
method such as an isoelectric focusing (IEF) study may be
needed to confirm the presence of any b-lactamase. We
will consider this in subsequent studies. Second, patients
using oral antibiotics for community-onset UTI were not
included in this study. Third, we excluded special groups
such as children, pregnant or lactating women, people with
complete obstruction of the urinary tract, and patients
ESBL-producing uropathogens 173with a perinephric or intrarenal abscess, or male patients
with prostatitis. Therefore, our findings could only apply to
the specific group of adults with a diagnosis of urinary tract
infection caused by ESBL-producing Enterobacteriaceae
under parental antibiotic use.
Choosing empirical antibiotics appropriately can be
challenging in a busy, high-volume emergency department
of a tertiary hospital. Our study may help clinicians in such
a setting to identify patients with urinary tract infection
that is likely caused by ESBL-producing pathogens.
In conclusion, in the community, ESBL pathogens have
become a serious issue. Clinicians should be aware of the
emerging problem of antibiotic resistance. Further studies
on the epidemiological trend of ESBL pathogens in
community-acquired UTI are crucial.
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